Natriumchloride Kabipac (Sodium Chloride)

The sodium chloride in Natriumchloride Kabipac dissociates into sodium and chloride ions after infusion, directly raising extracellular concentrations. This osmotic effect expands blood volume, improves hemodynamics, and corrects electrolyte deficits, supporting normal cellular and metabolic functions.

The dose of Natriumchloride Kabipac is determined by the prescribing clinician based on the patient’s fluid status, electrolyte levels, and clinical condition. Dosage is individualized and should follow the prescriber’s instructions.

Safety data for Natriumchloride Kabipac in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any potential risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To order Natriumchloride Kabipac, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Natriumchloride Kabipac is an isotonic sodium chloride injection similar to standard 0.9% saline. Compared with hypertonic or balanced electrolyte solutions, it provides a straightforward sodium and chloride replacement without additional buffers or potassium, making it suitable for simple volume expansion and electrolyte repletion.

Natriumchloride Kabipac should be stored at 2‑8 °C, kept refrigerated, protected from light, and must not be frozen or shaken. Maintain the original packaging to preserve sterility until use.

The product is administered intravenously by slow infusion through a suitable IV line. Administration rate and volume are determined by the prescriber based on the patient’s clinical needs and monitoring parameters.

Serious risks include hypernatremia, hyperchloremic metabolic acidosis, and rare allergic reactions such as anaphylaxis. Prompt recognition of symptoms and appropriate monitoring are essential to mitigate these risks.

Patients with known hypersensitivity to sodium chloride solutions, severe fluid overload, uncontrolled hypertension, or those for whom rapid volume expansion is contraindicated should not receive Natriumchloride Kabipac unless specifically directed by a qualified clinician.